Bernstein Remains a Hold on Vertex Pharmaceuticals (VRTX)
Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...
Orna Therapeutics, Vertex Pharma Enter Three-year Research Collaboration - Quick Facts
Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...
Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors
The stock's fall snapped a three-day winning streak.
Zacks.com on MSN15h
Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note
Vertex Pharmaceuticals (VRTX) ended the recent trading session at $402.49, demonstrating a -1.13% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.55%. On ...
Seeking Alpha22h
VRTX Vertex Pharmaceuticals Incorporated
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.